Valgimigli et al. Eur Heart J. 2022
Featured products: Ultimaster™ Tansei™ Sirolimus Eluting Coronary Stent System, Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System
Patients undergoing percutaneous coronary intervention (PCI) with severe coronary artery disease (CAD) and challenging lesion subsets require complex procedures and remain at increased risk of short and long-term adverse ischaemic events.
MASTER DAPT was an investigator‑initiated, randomised, open‑label trial conducted in patients at high bleeding risk after the implantation of an Ultimaster™/Ultimaster™ Tansei™ DES.
The trial compared abbreviated (1 month) dual antiplatelet therapy (DAPT) with non-abbreviated (3-12 months) DAPT.
The primary results showed that 1 month of DAPT was non-inferior to treatment continuation for at least 2 additional months for the occurrence of net adverse clinical events (NACE) and major adverse cardiac and cerebral events (MACCE) and reduced major or clinically relevant non-major bleeding (MCB) in the overall high bleeding risk population.
The aim of this prespecified subgroup analysis was to assess the consistency of the treatment effects of 1-month vs. a more prolonged DAPT duration based on PCI and patient (complex PCI and/or acute coronary syndrome (ACS)) complexity.
Complex PCI was defined as 3-vessels treated, ≥ 3 stents implanted, ≥3 lesions treated, bifurcation with two stents implanted, total stent length > 60 mm, or chronic total occlusion (CTO).
- No interaction between the three ranked primary endpoints and complex PCI and/or ACS.
One-month DAPT after PCI with the Ultimaster™ Family DES in high bleeding risk patients was associated with:
- Similar net adverse clinical events (NACE)
- Similar major adverse cardiac or cerebral events (MACCE)
- Lower bleeding rates (MCB)
